Bart Neyns
Overview
Explore the profile of Bart Neyns including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
11974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Long G, Shklovskaya E, Satgunaseelan L, Mao Y, Pires da Silva I, Perry K, et al.
Nat Med
. 2025 Feb;
PMID: 40016450
Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many...
2.
Hauschild A, Garbe C, Ascierto P, Demidov L, Dreno B, Dummer R, et al.
Lancet Oncol
. 2025 Jan;
26(1):12-14.
PMID: 39756440
No abstract available.
3.
Dirven I, Pierre E, Vander Mijnsbrugge A, Vounckx M, Kessels J, Neyns B
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682270
Background: There are no active treatment options for patients with progressive melanoma brain metastases (MBM) failing immune checkpoint blockade (ICB) and BRAF/MEK inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-kinase inhibitor...
4.
Handel E, McKeown J, Wei J, Kankaria R, Burnette H, Johnson D, et al.
Eur J Cancer
. 2024 Dec;
215:115171.
PMID: 39667250
Immune checkpoint inhibitors (ICI) can achieve durable responses in patients with advanced melanoma, and results from clinical trials suggest cure may be possible for a subset of patients. Despite clinical...
5.
Meeus F, Funeh C, Awad R, Zeven K, Autaers D, De Becker A, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39562005
Background: Glioblastoma is the most common lethal primary brain tumor, urging evaluation of new treatment options. Chimeric antigen receptor (CAR)-T cells targeting B7 homolog 3 (B7-H3) are promising because of...
6.
Duerinck J, Lescrauwaet L, Dirven I, Delhaye J, Stevens L, Geeraerts X, et al.
Neuro Oncol
. 2024 Oct;
26(12):2208-2221.
PMID: 39406392
Background: Recurrent high-grade glioma (rHGG) lacks effective life-prolonging treatments and the efficacy of systemic PD-1 and CTLA-4 immune checkpoint inhibitors is limited. The multi-cohort Glitipni phase I trial investigates the...
7.
Awada G, Dirven I, Schwarze J, Tijtgat J, Fasolino G, Kockx M, et al.
JCO Precis Oncol
. 2024 Oct;
8:e2300493.
PMID: 39374099
Purpose: Patients with / wild-type melanoma who progress after immune checkpoint inhibitors (ICIs) have a poor prognosis. MEK inhibition has shown activity in this patient population but is associated with...
8.
Woodford R, McKeown J, Hoeijmakers L, Mangana J, Dimitriou F, Allayous C, et al.
Eur J Cancer
. 2024 Oct;
212:115055.
PMID: 39366209
Introduction: Approximately 50 % of resected stage II-IV melanoma patients develop recurrent disease by 5 years despite adjuvant anti-PD-1 therapy. Data to define best management of recurrences is lacking. Methods:...
9.
Dirven I, Calliauw E, Awada G, Vounckx M, Kessels J, Neyns B
Front Med (Lausanne)
. 2024 Sep;
11:1436774.
PMID: 39314226
Clonal MAPK-pathway activating mutations in the gene are present in approximately 9% of cutaneous melanomas. These mutations are divided into three classes: RAF-dependent, RAF-regulated, RAF-independent. Cell lines with class-2 or...
10.
Dirven I, Vounckx M, Kessels J, Lauwyck J, Awada G, Vanbinst A, et al.
Pigment Cell Melanoma Res
. 2024 Jul;
37(6):822-830.
PMID: 38990845
Leptomeningeal melanoma metastases (LMM) are associated with poor survival. Diagnosis is based on clinical presentation, brain MRI and cerebrospinal fluid (CSF) analysis. Inconclusive findings at initial presentation can delay treatment....